Unicycive Therapeutics, Inc. (UNCY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Unicycive Therapeutics, Inc., a Delaware corporation, on July 2, 2026. The report discloses preliminary financial results for the second quarter ended June 30, 2026. The company is listed on the Nasdaq Capital Market under the symbol UNCY and identifies itself as an emerging growth company.
Key Financial Metrics
- Cash Balance: Approximately $61.4 million as of June 30, 2026.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: Beyond the cash balance, the filing text does not provide a clear value for total debt, current liabilities, or other liquidity metrics.
Material Changes
The filing text does not provide a clear value for material changes in financial position or operating results compared to the prior comparable period. The report focuses solely on the disclosure of the ending cash balance and the preliminary nature of the Q2 results.
Guidance, Outlook, and Risks
Management Commentary: Management states that the preliminary results for the second quarter ended June 30, 2026, are their responsibility.
Audit Status: The independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures regarding these preliminary results and has expressed no opinion or assurance on them.
Guidance and Risks: The filing text does not provide a clear value for future guidance, specific risk factors, or contingencies beyond the standard disclaimer regarding unaudited preliminary data.
Investor Verification Checklist
- Verify the full audited financial statements for the quarter ended June 30, 2026, once filed in the 10-Q.
- Confirm the company's burn rate and runway based on the $61.4 million cash balance.
- Review the upcoming 10-Q for details on revenue, expenses, and net loss, which are absent in this 8-K.
- Monitor for any updates on clinical trial progress or regulatory milestones not detailed in this summary.